Advanced Glycation End-Products and Arterial Stiffness in Hypertension

McNulty, Marie; Mahmud, Azra; Feely, J.

doi:10.1016/j.amjhyper.2006.08.009

Cited by 138 publications

(90 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In participants of 70 years or older, carotid femoral PWV increased with higher levels of plasma AGEs concentration (P =0.02), a result not observed in younger age groups. Taking into account the results of our study 11) and other studies 13,14) , we believe that AGEs accumulate with aging and high cholesterol, and are associated with arterial wave reflections and, in an age-dependent manner, arterial stiffness. In further analysis in the same study population, plasma AGEs concentration was associated with central-to-brachial blood pressure amplification, as expressed by central-tobrachial pulse pressure ratio 12) .…”

Section: Emerging Risk Factorssupporting

confidence: 69%

Research for Vascular Failure: Current Topics in China

Wang

2018

Vasc Fail

View full text Add to dashboard Cite

Abstract:"Vascular failure" is a new concept, which can be used interchangeably with "vascular dysfunction". It can be evaluated with several arterial properties, such as endothelial function, arterial stiffness, wave reflection, and intima-media thickness. The current Chinese hypertension guidelines recommend some of these vascular properties for risk assessment and stratification in the management of hypertension. However, none of these measurements are routine in the clinical setting in China, because of the lack of available devices and insufficient knowledge on the clinical efficacy of these vascular measurements. In order to improve the use of these vascular measurements in clinical practice, therapeutic research is required to prove reversibility of vascular failure by either pharmacological treatments or lifestyle modifications. Other research directions include identification of emerging risk factors, risk prediction and prevention with vascular measurements, and the development of newer, more accurate and efficient devices.

show abstract

Section: Emerging Risk Factorssupporting

confidence: 69%

Research for Vascular Failure: Current Topics in China

Wang

2018

Vasc Fail

View full text Add to dashboard Cite

show abstract

“…These factors determine alterations in collagen IV turnover (22). Extra-cellular matrix (ECM) is highly susceptible for glycation because of its slow turnover rate, and AGE accumulation is responsible for the formation of cross-links (23), with subsequent mechanical alterations (24) leading to decreased elasticity and increased stiffness of vessels (25) and myocardium (26), increased thickness, narrowing of the vessel lumen (27), development of glomerular sclerosis and atherosclerosis. AGE formation in ECM also interferes with matrix-cell interactions, with alterations in signaling and adhesion; these may be an important initial event in diabetic microangiopathy (28).…”

Section: Accumulation Of Ages In the Extracellular Matrixmentioning

confidence: 99%

Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease

et al. 2015

View full text Add to dashboard Cite

Context: Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and neurological complications in diabetic and non-diabetic patients. AGEs proved to be a marker of negative outcome in both diabetes management and surgical procedures in these patients. The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports. Evidence Acquisition: Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles. Results: Pharmacological approaches in humans include aminoguanidine, pyridoxamine, benfotiamine, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, statin, ALT-711 (alagebrium) and thiazolidinediones. The most recent promising antiAGEs agents are statins, alagebrium and thiazolidinediones. The role of AGEs in disease and new compounds interfering with their effects are currently under investigation in preclinical settings and these newer anti-AGEs drugs would undergo clinical evaluation in the next years. Compounds with anti-AGEs activity but still not available for clinical scenarios are ALT-946, OPB-9195, tenilsetam, LR-90, TM2002, sRAGE and PEDF. Conclusions: Despite most studies confirm the efficacy of these pharmacological approaches, other reports produced conflicting evidences; in almost any case, these drugs were well tolerated. At present, AGEs measurement has still not taken a precise role in clinical practice, but its relevance as a marker of disease has been widely shown; therefore, it is important for clinicians to understand the value of new cardiovascular risk factors. Findings from the current and future clinical trials may help in determining the role of AGEs and the benefits of anti-AGEs treatment in cardiovascular disease.

show abstract

“…В настоящее время к основ-ническими проявлениями ИБС при НТ болезнь диагностируется лишь в 10-20% случаев [424].…”

Section: генетические синдромы с риском жизнеугрожающих аритмий (канаunclassified

National Russian Guidelines on Application of the Methods of Holter Monitoring in Clinical Practice

Макаров¹,

Комолятова²,

Куприянова³

et al. 2014

Russ J Cardiol

View full text Add to dashboard Cite

Advanced Glycation End-Products and Arterial Stiffness in Hypertension

Cited by 138 publications

References 30 publications

Research for Vascular Failure: Current Topics in China

Research for Vascular Failure: Current Topics in China

Pharmacologic approaches against Advanced Glycation End Products (AGEs) in diabetic cardiovascular disease

National Russian Guidelines on Application of the Methods of Holter Monitoring in Clinical Practice

Contact Info

Product

Resources

About